165 related articles for article (PubMed ID: 31887226)
1. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Pareja F; Toss MS; Geyer FC; da Silva EM; Vahdatinia M; Sebastiao APM; Selenica P; Szatrowski A; Edelweiss M; Wen HY; Mihai R; Varga Z; Foschini MP; Rubin BP; Ellis IO; Chandarlapaty S; Jungbluth AA; Brogi E; Weigelt B; Reis-Filho JS; Rakha EA
Histopathology; 2020 May; 76(6):865-874. PubMed ID: 31887226
[TBL] [Abstract][Full Text] [Related]
2. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
[TBL] [Abstract][Full Text] [Related]
3. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Geyer FC; Li A; Papanastasiou AD; Smith A; Selenica P; Burke KA; Edelweiss M; Wen HC; Piscuoglio S; Schultheis AM; Martelotto LG; Pareja F; Kumar R; Brandes A; Fan D; Basili T; Da Cruz Paula A; Lozada JR; Blecua P; Muenst S; Jungbluth AA; Foschini MP; Wen HY; Brogi E; Palazzo J; Rubin BP; Ng CKY; Norton L; Varga Z; Ellis IO; Rakha EA; Chandarlapaty S; Weigelt B; Reis-Filho JS
Nat Commun; 2018 May; 9(1):1816. PubMed ID: 29739933
[TBL] [Abstract][Full Text] [Related]
4. The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma.
Nakaguro M; Tanigawa M; Hirai H; Yamamoto Y; Urano M; Takahashi RH; Sukeda A; Okumura Y; Honda S; Tasaki K; Shimizu A; Tsukahara K; Tada Y; Matsubayashi J; Faquin WC; Sadow PM; Nagao T
Am J Surg Pathol; 2021 Jul; 45(7):885-894. PubMed ID: 33481388
[TBL] [Abstract][Full Text] [Related]
5. HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.
Bièche I; Coussy F; El-Botty R; Vacher S; Château-Joubert S; Dahmani A; Montaudon E; Reyes C; Gentien D; Reyal F; Ricci F; Nicolas A; Marchio C; Vincent-Salomon A; Laé M; Marangoni E
J Hematol Oncol; 2021 Sep; 14(1):143. PubMed ID: 34496925
[TBL] [Abstract][Full Text] [Related]
6. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
7. NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.
Saliba M; Katabi N; Dogan S; Xu B; Ghossein RA
Histopathology; 2021 Oct; 79(4):650-660. PubMed ID: 33960437
[TBL] [Abstract][Full Text] [Related]
8. Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.
Baum JE; Sung KJ; Tran H; Song W; Ginter PS
Int J Surg Pathol; 2019 Jun; 27(4):441-445. PubMed ID: 30585117
[TBL] [Abstract][Full Text] [Related]
9. Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues.
Peralta S; Marcinczyk MM; Katt WP; Duhamel GE
Front Vet Sci; 2023; 10():1281022. PubMed ID: 37901104
[TBL] [Abstract][Full Text] [Related]
10. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
11. A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.
Watanabe S; Otani T; Iwasa T; Takahama T; Takeda M; Sakai K; Nishio K; Ito A; Nakagawa K
Clin Breast Cancer; 2019 Oct; 19(5):e589-e592. PubMed ID: 31301988
[No Abstract] [Full Text] [Related]
12. Assessment of
Pareja F; Geyer FC; Brown DN; Sebastião APM; Gularte-Mérida R; Li A; Edelweiss M; Da Cruz Paula A; Selenica P; Wen HY; Jungbluth AA; Varga Z; Palazzo J; Rubin BP; Ellis IO; Brogi E; Rakha EA; Weigelt B; Reis-Filho JS
NPJ Breast Cancer; 2019; 5():6. PubMed ID: 30675516
[TBL] [Abstract][Full Text] [Related]
13. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
[TBL] [Abstract][Full Text] [Related]
14. MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma.
Baraban E; Zhang PJ; Jaffer S; Lubin D; Feldman M; Bleiweiss IJ; Nayak A
Histopathology; 2018 Dec; 73(6):897-903. PubMed ID: 30003572
[TBL] [Abstract][Full Text] [Related]
15. Problematic breast tumors reassessed in light of novel molecular data.
Pareja F; Weigelt B; Reis-Filho JS
Mod Pathol; 2021 Jan; 34(Suppl 1):38-47. PubMed ID: 33024304
[TBL] [Abstract][Full Text] [Related]
16. Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry.
Crescenzi A; Fulciniti F; Bongiovanni M; Giovanella L; Trimboli P
Endocr Pathol; 2017 Mar; 28(1):71-74. PubMed ID: 28064410
[TBL] [Abstract][Full Text] [Related]
17. Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity.
Ginter PS; McIntire PJ; Kurtis B; Mirabelli S; Motanagh S; Hoda S; Elemento O; Shin SJ; Mosquera JM
Mod Pathol; 2020 Sep; 33(9):1764-1772. PubMed ID: 32355271
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors.
Oishi N; Kondo T; Vuong HG; Nakazawa T; Mochizuki K; Kasai K; Inoue T; Tahara I; Hirokawa M; Miyauchi A; Katoh R
Hum Pathol; 2016 Jul; 53():51-7. PubMed ID: 26980032
[TBL] [Abstract][Full Text] [Related]
19. HRAS mutations in epithelial-myoepithelial carcinoma.
Chiosea SI; Miller M; Seethala RR
Head Neck Pathol; 2014 Jun; 8(2):146-50. PubMed ID: 24277618
[TBL] [Abstract][Full Text] [Related]
20. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
